Jane Pritchett Henderson
Jane Pritchett Henderson has over 28 years of experience in health care life sciences with a unique combination of extensive investment banking, corporate biopharmaceutical senior management and Board director experience – making her a trusted advisor to numerous companies.
Jane is currently the Chief Financial Officer of Turnstone Biologics. Prior to that position, she served as Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics and as Chief Financial and Business Officer at Kolltan Pharmaceuticals, until its sale to Celldex Therapeutics.
Previously, Jane served in various financial and business development leadership roles at ISTA Pharmaceuticals, Axerion Pharmaceuticals and Panacos Pharmaceuticals. Jane also has an extensive healthcare investment banking background in addition to her industry experience, including execution of over 95 M&A, advisory and financing transactions over a nearly 20-year career at HSBC, CIBC, Lehman Brothers and Salomon Brothers, collectively. Jane currently serves on the Board of Directors of IVERIC Bio (formerly Ophthotech) and Sesen Bio (formerly Eleven Biotherapeutics).
Ms. Henderson has a B.S. from Duke University.